Publications
358 results found
Agache I, Song Y, Rocha C, et al., 2020, Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma, ALLERGY, Vol: 75, Pages: 1058-1068, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 55
Bousquet J, Farrell J, Illario M, et al., 2020, Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing, ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, Vol: 12, Pages: 238-258, ISSN: 2092-7355
- Author Web Link
- Cite
- Citations: 4
Konradsen JR, Grundstr J, Hellkvist L, et al., 2020, Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: A randomized trial, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 145, Pages: 1005-+, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 25
Layhadi J, Lobo RM, Parkin R, et al., 2020, Allergenicity and Safety Profile of Depigmented-Polymerized Phleum pratense Extract for Use in Allergen-Specific Immunotherapy Treatments, Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), Publisher: MOSBY-ELSEVIER, Pages: AB60-AB60, ISSN: 0091-6749
Parkin R, Eguiluz-Gracia I, Jaen MT, et al., 2020, Nasal Allergen Neutralizing Antibodies Correlate Closely with Tolerated Intranasal Allergen Challenge Dose Following Grass Pollen Subcutaneous Immunotherapy in Patients with Local Allergic Rhinitis, Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), Publisher: MOSBY-ELSEVIER, Pages: AB184-AB184, ISSN: 0091-6749
Bousquet J, Schunemann HJ, Togias A, et al., 2020, Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 145, Pages: 70-+, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 200
Pfaar O, Agache I, de Blay F, et al., 2019, Perspectives in allergen immunotherapy: 2019 and beyond, ALLERGY, Vol: 74, Pages: 3-25, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 87
Saleh AD, Durham SR, Shamji MH, et al., 2019, PEAK NASAL INSPIRATORY FLOW AND NASAL CYTOKINES ARE USEFUL BIOMARKERS OF NASAL INFLAMMATION IN CYSTIC FIBROSIS GENE THERAPY, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A13-A13, ISSN: 0040-6376
Agache I, Annesi-Maesano I, Bonertz A, et al., 2019, Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases, ALLERGY, Vol: 74, Pages: 2064-2076, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 33
Hj Awg Sharif H, Singh I, Kouser L, et al., 2019, Immunologic mechanisms of short-course of Lolium Perenne peptide immunotherapy: a randomized double-blind placebo-controlled trial, Journal of Allergy and Clinical Immunology, Vol: 144, Pages: 738-749, ISSN: 0091-6749
BackgroundThree-week, short-course of adjuvant-free hydrolysates of Lolium perenne peptide (LPP) immunotherapy for rhinoconjunctivitis with/without asthma over 4 physician visits is safe, well-tolerated and effective.ObjectiveTo investigate immunologic mechanisms of LPP immunotherapy in a subset of patients who participated in a Phase III, multicenter, randomized, double-blind, placebo-controlled trial (clinical.gov NCT02560948).MethodsParticipants were randomized to receive LPP (n=21) or placebo (PL; n=11) for 3 weeks over 4 visits. Grass pollen-induced basophil, T and B cell responses were evaluated before (V2), end of treatment (V6) and after the pollen season (V8).ResultsCombined symptom and rescue medication scores (CSMS) were lower during the peak (-35.1%, P=.03) and throughout pollen season (-53.7%, P=.03) in LPP- compared to PL-treated group. CD63+ and CD203cbrightCRTH2+basophils were decreased following LPP treatment at V6 (all, P<.0001) and V8 (all, P<.001), compared to V2. No change in PL-treated group was observed. Blunting of seasonal increases of grass pollen-specific IgE was observed in LPP- but not PL-treated group. LPP immunotherapy but not PL was associated with a reduction of IL-4+ Th2 (V6, P=.02), IL-4+ (V6, P=.001;V8, P=.0095) and IL-21+ (V6, P=.0002) T follicular helper cells. Induction of FoxP3+, follicular regulatory T and IL-10+ Breg cells were observed at V6 (all, P<.05) and V8 (all, P<.05) in LPP-treated group. Induction of regulatory B cells was associated with allergen neutralizing IgG4 blocking antibodies.ConclusionFor the first time, we demonstrate that the immunological mechanisms of LPP immunotherapy are underscored by immune modulation in the T and B cell compartments which is necessary for its effect.
Bousquet J, Nhan P-T, Bedbrook A, et al., 2019, Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2), JOURNAL OF THORACIC DISEASE, Vol: 11, Pages: 4072-4084, ISSN: 2072-1439
- Author Web Link
- Cite
- Citations: 9
Bousquet J, Pfaar O, Togias A, et al., 2019, 2019 ARIA Care pathways for allergen immunotherapy, ALLERGOLOGIE, Vol: 42, Pages: 404-425, ISSN: 0344-5062
- Author Web Link
- Cite
- Citations: 2
Witmer M, Kearney P, Getts RC, et al., 2019, Predicting eliciting dose at food challenge using epitope mapping in peanut-allergic children, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 152-152, ISSN: 0105-4538
Layhadi JA, Sharif H, Singh I, et al., 2019, Immunomodulatory properties of lolium perenne peptides for the treatment of seasonal allergic rhinitis, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 79-79, ISSN: 0105-4538
Kirtland M, Vila-Nadal G, Tsitoura D, et al., 2019, A novel toll-like receptor 7 agonist can ameliorate phleum pratense induced allergic responses in vitro, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 80-80, ISSN: 0105-4538
Layhadi JA, Paques C, Destine A, et al., 2019, The allergenicity and immunogenicity of peanut and house dust mite peptides generated by a novel technology platform: The future of immunotherapy treatments, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 117-118, ISSN: 0105-4538
Layhadi JA, Thomsen I, Kappen J, et al., 2019, Broad immunoglobulin G repertoire in chronic rhinosinusitis with nasal polyps regulates pro-inflammatory IgE responses, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 53-53, ISSN: 0105-4538
Sharif H, Acharya S, Dhondalay GK, et al., 2019, Altered chromatin landscape in T follicular cells in seasonal allergic rhinitis and following allergen-specific immunotherapy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 64-65, ISSN: 0105-4538
Yi Y, Sharif H, Krasner-Macleod S, et al., 2019, Immunomodulation of CD4+CXCR5+PD-1+T follicular helper (Tfh) and CD4+CXCR5+PD-1+FoxP3+T follicular regulatory (Tfr) cell responses in grass pollen allergy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 199-199, ISSN: 0105-4538
Parkin R, Eguiluz-Gracia I, Tang J, et al., 2019, Nasal allergen neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 119-119, ISSN: 0105-4538
Lenormand M, Layhadi JA, Hu J, et al., 2019, Epigenetic changes in SATB1 gene in FoxP3+regulatory T cells reflect immune tolerance status during grass pollen subcutaneous and sublingual immunotherapy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 63-64, ISSN: 0105-4538
Bousquet J, Nhan P-T, Bedbrook A, et al., 2019, Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases, JOURNAL OF THORACIC DISEASE, Vol: 11, Pages: 3633-3641, ISSN: 2072-1439
- Author Web Link
- Cite
- Citations: 8
Stranzl T, Shamji MH, Ohashi-Doi K, et al., 2019, IgE and IgG4 response uniformity allows for subject-specific measure of exposure to sublingual allergen immunotherapy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 191-191, ISSN: 0105-4538
Skypala IJ, Cecchi L, Shamji M, et al., 2019, Lipid Transfer Protein allergy in the United Kingdom; characterisation and comparison with a matched Italian cohort, Allergy, Vol: 74, Pages: 1340-1351, ISSN: 0105-4538
BACKGROUND: Although pollen-related food allergy occurs in all European populations, Lipid Transfer Protein (LTP) allergy is considered to manifests mainly in Mediterranean countries. We aimed to characterise adults presenting with LTP allergy in a Northern European country. METHOD: The clinical history and sensitisation patterns of subjects born and residing in the United Kingdom (UK), with a prior diagnosis of LTP allergy and sensitisation to the peach LTP allergen Pru p 3, were compared to UK subjects with pollen food syndrome (PFS). The sensitisation patterns were also evaluated against a matched cohort of Italian subjects diagnosed with LTP allergy. RESULTS: None of the 15 UK PFS subjects had a positive SPT to LTP-enriched peach reagent, compared to 91% of the 35 UK LTP subjects. The UK LTP cohort were also more likely to have positive skin prick tests to barley, tomato and cashew nut and sensitisation to the LTP allergens in peach, walnut, mugwort and plane tree These sensitisation patterns to individual allergens were not significantly different from those obtained from the Italian LTP subjects, with significant correlations between Pru p 3 and the LTP allergens in peanuts, walnuts, plane tree and mugwort in both groups. CONCLUSION: Native UK subjects with LTP allergy are not dissimilar to those with LTP allergy in Southern Europe. Testing to LTP-enriched peach SPT reagent and/or LTP allergens in peach, walnut, mugwort and plane tree may enhance diagnostic accuracy.
Shamji MH, Francis JN, 2019, Measurement of Allergen-Specific Inhibitory Antibody Activity., Methods Mol Biol, Vol: 2020, Pages: 33-43
Specific allergen immunotherapy (AIT) is an effective treatment for IgE-mediated allergic diseases and involves T- and B-cell-mediated events. IgE receptors on the surface of antigen-presenting cells facilitate the presentation of allergens in the presence of specific IgE antibody resulting in T-cell activation. Interference with these IgE-dependent mechanisms by "blocking" IgG antibodies suppresses pro-inflammatory Th2 cell responses and manifests as a reduction in allergic responses in vivo.In vitro assays used to measure the inhibition of binding of allergen-IgE complexes have previously utilized proliferation of antigen-specific T-cell clones as an assay readout. Here we describe two simplified assays to measure allergen binding without the complexity of generating T-cell clones. The IgE-facilitated allergen binding assay (IgE-FAB) utilizes flow cytometry to measure the binding of allergen-IgE complexes to EBV-transformed B cells. The enzyme-linked immunosorbent-facilitated antigen binding (ELIFAB) assay uses standard ELISA-based techniques to measure allergen-IgE binding to plate-bound CD23, the low-affinity IgE receptor expressed on B cells.
Shamji MH, Thomsen I, Layhadi JA, et al., 2019, Broad immunglobulin G repertoire in chronic rhinosinusitis with nasal polyps regulates pro-inflammatory IgE responses, Journal of Allergy and Clinical Immunology, Vol: 143, Pages: 2086-2094.e2, ISSN: 0091-6749
BackgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by local production of polyclonal IgE-idiotypes. Whilst tissue IgE concentrations can be in the range of several thousand kU/L, the regulatory mechanisms by which IgE-mediated inflammation is controlled in the nasal polyps is not well understood.ObjectiveWe sought to determine whether locally induced IgG antibodies in the nasal polyps can inhibit IgE-mediated pro-allergic response.MethodsNasal polyp homogenates were collected from grass pollen allergics with CRSwNP and non-allergic controls. IgE levels were measured by ISAC. IgE-containing nasal polyp homogenates, with/without IgG depletion, were evaluated for their capacity to promote IgE-facilitated allergen presentation, basophil activation and histamine release. Local IgE and IgG repertoires were evaluated by Immunoglobulin 454 sequencing.ResultsWe show that IgG plays a key role in controlling IgE-mediated inflammatory responses in nasal polyps. Depletion of IgG from nasal homogenates resulted in an increase in CD23-mediated IgE-facilitated allergen binding to B cells (IgE-FAB), but also enhanced FcεRI-mediated allergen driven basophil activation and histamine release. A similar response was observed in relation to specific IgE antibodies to Staphylococcus aureus (SE-IgE). The capacity of IgG in nasal polyps to limit IgE-mediated inflammation is based on the fact that IgG repertoires widely share the antigen targets with the IgE repertoires, in both allergic and non-allergic subjects.ConclusionPolyclonal IgE idiotypes in CRSwNP are functional, promote IgE-mediated pro-allergic inflammation and are partially antagonized by corresponding IgG-idiotypes. This is most likely due to the fact that IgE and IgG clonotypes are widely shared in nasal polyps.
Eguiluz-Gracia I, Layhadi JA, Rondon C, et al., 2019, Mucosal IgE immune responses in respiratory diseases, CURRENT OPINION IN PHARMACOLOGY, Vol: 46, Pages: 100-107, ISSN: 1471-4892
- Author Web Link
- Cite
- Citations: 21
Bousquet J, Pfaar O, Togias A, et al., 2019, 2019 ARIA Care pathways for allergen immunotherapy., Allergy
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients. This article is protected by copyright. All rights reserved.
Rauber MM, Wu HK, Adams B, et al., 2019, Birch pollen allergen-specific immunotherapy with glutaraldehyde-modified allergoid induces IL-10 secretion and protective antibody responses., Allergy
Shamji MH, Layhadi JA, Achkova D, et al., 2019, Role of interleukin-35 in sublingual allergy immunotherapy, Journal of Allergy and Clinical Immunology, Vol: 143, Pages: 1131-1142.e4, ISSN: 0091-6749
BACKGROUND: Grass pollen-specific immunotherapy involves immunomodulation of allergen-specific T helper 2 cell (Th2) responses and induction of IL-10+ and/or TGF-β+CD4+CD25+ regulatory T cells (iTregs). IL-35+CD4+CD25+Foxp3- T (iTR35) cells have been reported as a novel subset of iTregs with modulatory characteristics. OBJECTIVE: To investigate the mechanisms underlying the induction and maintenance of immunological tolerance induced by IL-35 and iTR35 cells. METHODS: The biological effects of IL-35 was assessed on Group II innate lymphoid cells (ILC2s), dendritic cells (DCs) primed with TSLP, IL-25 and IL-33, B and Th2 cells by flow cytometry and qRT-PCR. Grass pollen-driven Th2 cell proliferation and cytokine production was measured by [3H]-thymidine and Luminex MagPix, respectively. iTr35 cells were quantified in grass pollen allergics (SAR, n=16), sublingual immunotherapy-treated patients (SLIT, n=16) and non-atopic controls (NAC, n=16). RESULTS: SAR had elevated proportions of ILC2s (P=.002), IL5+ (P=.042), IL13+ (P=.042) and IL5+IL13+ILC2s (P=.003) compared to NAC. IL-35 inhibited IL-5 and IL-13 production by ILC2s in the presence of IL-25 or IL-33 (P=.031) and allergen-driven Th2 cytokines by Teff cells. IL-35 inhibited CD40L, IL-4 and IL-21-mediated IgE production by B cells (P=.015), allergen-driven T cell proliferation (P=.001) and Th2 cytokine production by primed DCs. iTR35 cells suppressed Th2 cell proliferation and cytokine production. In addition, allergen-driven IL-35 levels and iTR35 cells were elevated in SLIT (all, P<.001) and NAC (all, P<.001) compared to SAR. CONCLUSION: IL-35 and iTR35 cells are potential novel immune-regulators induced by SLIT. The clinical relevance of SLIT may be underscored by the restoration of protective iTR35 cells.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.